Oncolys BioPharma Inc.
4588・Growth Market・Pharmaceuticals
Drug Discovery Business (Oncolys BioPharma Inc., single segment)
A research-and-development-driven drug discovery biotech company (single segment) specializing in virus-based drug discovery
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (cumulative Q1, FY2026 (ending December 2026)) | ¥3 million | ¥0 million (Q1, FY2025 (ending December 2025)) | ↑ |
| Operating loss (cumulative Q1, FY2026 (ending December 2026)) | -¥420 million | -¥785 million (Q1, FY2025 (ending December 2025)) | ↑ |
| Ordinary loss (cumulative Q1, FY2026 (ending December 2026)) | -¥413 million | -¥810 million (Q1, FY2025 (ending December 2025)) | ↑ |
| Quarterly net loss (cumulative Q1, FY2026 (ending December 2026)) | -¥414 million | -¥811 million (Q1, FY2025 (ending December 2025)) | ↑ |
| R&D expenses (cumulative Q1, FY2026 (ending December 2026)) | ¥245 million | — (year-on-year comparison figure not disclosed) | ↓ |
| Cash and deposits (as of March 31, 2026) | ¥3,536 million | ¥3,675 million (December 31, 2025) | ↓ |
| Total assets (as of March 31, 2026) | ¥4,528 million | ¥4,556 million (December 31, 2025) | ↓ |
| Net assets (as of March 31, 2026) | ¥3,593 million | ¥4,000 million (December 31, 2025) | ↓ |
| Equity ratio (as of March 31, 2026) | 79.2% | 87.6% (December 31, 2025) | ↓ |
| Quarterly net loss per share | -¥14.16 | -¥32.66 (Q1, FY2025 (ending December 2025)) | ↑ |
Business Details
The company's principal business areas are "cancer virotherapy" centered on the oncolytic virus OBP-301 and the LINE-1 inhibitor OBP-601, among others. The revenue model is transitioning to a hybrid of the licensing-type (upfront payments, milestones, royalties) and pharmaceutical-company-type (in-house manufacturing and sales). OBP-301 has already been filed with the PMDA in December 2025 as a regenerative medicine product for the treatment of esophageal cancer, and the company aims to begin domestic sales in 2026. The loss-making structure, in which R&D expenses substantially exceed revenue, continues.
Recent Overview
Conformity inspection following the OBP-301 approval application was determined to be "conforming"; loss amount roughly halved year on year
Net sales for the January-March 2026 period were ¥3 million (zero in the same period of the prior year), recorded for the first time. The operating loss narrowed substantially to ¥420 million from ¥785 million in the same period of the prior year. Regarding OBP-301, following the PMDA approval application filed in December 2025, the conformity document review and GCP on-site inspection were determined to be "conforming" in April 2026, confirming the reliability of the application materials. Additionally, in February 2026, the 18-month stability confirmation of the new formulation was completed. Liabilities increased 68.2% from the end of the prior period to ¥935 million, due to an increase in short-term borrowings and other factors.
Key Products
Growth Drivers
- Generation of product sales revenue through obtaining domestic manufacturing and marketing approval for OBP-301 (application filed; conformity inspection already determined "conforming"), targeting a 2026 sales launch
- Establishment of a domestic commercialization framework through the sales partnership with Fujifilm Toyama Chemical and supply chain arrangements with Mitsui-Soko Holdings (GCTP-compliant framework already established)
- Milestone revenue opportunities associated with Transposon's planned 2026 initiation of clinical trials for OBP-601 in PSP Phase 3, ALS Phase 2/3, and Alzheimer's disease Phase 2
- Future royalty income generation through the OBP-301 license to Taiwan's Medigen (concluded December 2024)
- Expansion of overseas licensing opportunities through accumulation of U.S. clinical data for OBP-301 (Phase 2 joint trial in gastric cancer with MSD, Phase 1 trial in esophageal cancer by NRG Oncology Group)
- Acceleration of OBP-601 development through strengthening of Transposon's funding base via the ARPA-H award and ADDF investment
- Planned 2026 initiation of an investigator-initiated Phase 1 trial for OBP-702 in pancreatic cancer led by Okayama University
Risks
- Risk of approval review delay or non-approval: the timing of sales launch could be significantly affected depending on the outcome of the PMDA's review of OBP-301
- Funding risk: with a small stable revenue base, the company continues to rely on ongoing equity issuances and borrowings, resulting in continued dilution risk and financial deterioration risk (equity ratio declined from 87.6% to 79.2%)
- Single-customer dependency risk: the majority of net sales are attributable to Transposon Therapeutics, so its management condition and strategic changes directly affect business performance
- Viral product manufacturing risk: commercial manufacturing of OBP-301 is outsourced to Henogen (Belgium), and manufacturing delays or quality issues could adversely affect stable supply
- Competitive risk: genetically modified herpesvirus products (such as Daiichi Sankyo's "Delytact Injection") have already been launched domestically, intensifying competition in the oncolytic virus therapy market
- Foreign exchange risk: overseas clinical trial and manufacturing costs are mainly denominated in foreign currencies, creating a structure in which R&D expenses increase as the yen depreciates (a foreign exchange gain of ¥9 million was recorded in the current first quarter)
- Uncertainty of milestone income: because performance can fluctuate significantly depending on OBP-301's overseas licensing terms, corporate actions by Transposon such as an IPO or M&A, and OBP-301's pricing and market rollout, the company continues to find it difficult to disclose earnings forecasts
Last updated: March 25, 2026